- Home
- HUBG vs BRVE Comparison
HUBG vs BRVE Comparison
Compare HUBG & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUBG | BRVE |
|---|---|---|
| Founded | 1971 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HUBG | BRVE |
|---|---|---|
| Price | $25.71 | $21.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $37.17 | ★ $45.25 |
| AVG Volume (30 Days) | ★ 976.3K | 377.4K |
| Earning Date | 11-06-2026 | 11-19-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,946,390,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.45 | N/A |
| P/E Ratio | $19.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.50 | $17.86 |
| 52 Week High | $53.26 | $32.00 |
Technical Indicators
Market Signals| Indicator | HUBG | BRVE |
|---|---|---|
| Relative Strength Index (RSI) | 30.73 | 47.65 |
| Support Level | N/A | $17.93 |
| Resistance Level | $27.61 | $29.71 |
| Average True Range (ATR) | 1.10 | 1.42 |
| MACD | 0.28 | 0.47 |
| Stochastic Oscillator | 18.89 | 84.52 |
Price Performance
Historical ComparisonAbout HUBG Hub Group Inc.
Hub Group ranks among the largest providers of rail intermodal service. Approximately 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
About BRVE Braveheart Bio Inc. Common Stock
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).